文献速递免疫规划传染病防控与疫情报告

黄热病疫苗突破感染八十年全面综述:突破与洞见

Breakthroughs and insights: A comprehensive review of yellow fever vaccine breakthrough infection across 8 decades.
PubMed 文献 · Vaccine · 2024-11-21

黄热病疫苗17D自1937年启用以来从未进行严格的III期临床试验,疫苗有效性缺乏前瞻性评估,突破感染是衡量疫苗失败的重要指标。该综述检索并分析了1944年至2023年间记录黄热病突破感染的19篇文献,包括13项队列研究、4篇病例报告和2个病例系列,报告疑似突破病例最多7793例、确诊最多773例,总结了近期疫情并指出研究局限与未来方向。

要点

  • 黄热病疫苗17D自1937年启用,从未进行严格的III期临床试验,也无前瞻性疫苗有效性评估。
  • 1944年至2023年间文献报告疑似突破病例最多7793例、确诊最多773例。
  • 综述纳入19篇文献,含13项队列研究、4篇病例报告和2个病例系列,并评估其方法学优缺点。

核心结论

  • 该综述基于1944年至2023年的19篇文献,更新了黄热病突破感染的认识,并指出需进一步推进该领域研究。

研究设计与样本

  • 文献综述,检索并分析1944年至2023年间记录黄热病突破感染的19篇论文,包括13项队列研究、4篇病例报告和2个病例系列。

主要发现

  • 文献报告疑似突破病例最多7793例,确诊突破病例最多773例。
  • 2015年美国免疫实践咨询委员会(ACIP)曾发布一份改变政策的报告,对黄热病突破感染进行了正式评估。

局限性

  • 黄热病疫苗17D自1937年引入以来从未进行严格的III期临床试验以评估安全性或有效性,也从未开展前瞻性疫苗有效性评估。
  • 自2015年美国免疫实践咨询委员会(ACIP)报告以来,尽管南美洲和非洲近期发生多次疫情,黄热病突破感染未再被综述。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The yellow fever vaccine 17D is one of the most successful live-attenuated vaccines ever developed, controlling mosquito-borne yellow fever virus and yellow fever disease worldwide. Introduced in 1937, 17D never underwent rigorous phase III clinical trials to evaluate safety or efficacy, and while protection in the field was quickly established, no prospective evaluation of vaccine efficacy has ever been conducted. One important measure of vaccine efficacy is breakthrough infection resulting from vaccine failure. Yellow fever breakthrough infection was previously formally evaluated in a policy-changing report conducted by the Advisory Committee on Immunization Practices in 2015 but has not been reviewed since despite several recent outbreaks in South America and Africa. To address this knowledge gap, we conducted a literature search and reviewed 19 papers documenting breakthrough yellow fever infection between 1944 and 2023. There were up to 7793 suspected and up to 773 confirmed breakthrough cases reported in the literature, including thirteen cohort studies, four case reports, and two case series, which we summarize, evaluate the approaches used, and identify strengths and weakness. This review provides an important and much needed update on the topic of yellow fever breakthrough infection, drawing from recent outbreaks, highlighting limitations, and suggesting future approaches to further advance the field.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Coulter FJ, Messer WB. Breakthroughs and insights: A comprehensive review of yellow fever vaccine breakthrough infection across 8 decades. Vaccine. 2024. PMID: 39577331. doi:10.1016/j.vaccine.2024.126423

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。